Is Johnson & Johnson a Buy After Its Latest Earnings Report?
Investors didn't seem to think so after the company published it.
Overview
On Wednesday morning, Johnson & Johnson (NYSE:JNJ) published its second-quarter earnings report, but this wasn't greeted warmly. Investors generally sold the stock, and by the end of that trading session, it was down by almost 3%.
This occurred on a broadly positive day for the stock market, with the bellwether S&P 500 index closing in positive territory. What did those selling investors find so unappealing about the pharmaceutical giant's figures, and was that reaction justified? Let's explore.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.